Skip to main content
. 2022 Sep 8;20:138. doi: 10.1186/s12964-022-00928-x

Fig. 5.

Fig. 5

Combination treatment with THZ1 and imatinib for GIST. A CCK-8 viability assay following treatment for 72 h with escalating concentrations of THZ1 and imatinib in GIST-T1 and GIST-882 cells. B GIST-T1 cells received single 20 nmol/L imatinib, THZ1 and a combination treatment for 72 h. GIST-882 cells received single 50 nmol/L imatinib, THZ1 and a combination treatment for 72 h. The cell viability of combination treatment group was significantly suppressed than monotherapy. C Synergy was calculated using CompuSyn, and a combination index value under 1.0 was considered to indicate synergy. D Immunoblotting analysis of cleaved caspase 3 and cleaved PARP protein expression after combination treatment with THZ1 and imatinib in GIST-T1 and GIST-882 cells for 24 h